Leprosy

Leprosy

WHO / Sejani Wilegoda
A person affected by leprosy in Moratuwa, Colombo District.

Leprosy remains an important cause of morbidity in socially vulnerable communities. Because of its long incubation period, it is typically observed among children after age two. In 2024, about 10 000 new child cases were reported globally, with 2.7% of affected children presenting permanent impairment or disability. Contact screening along with post-exposure prophylaxis with single-dose rifampicin are key WHO-recommended interventions, alongside management of complications such as leprosy reactions.

WHO recommends multidrug therapy (MDT) with rifampicin, clofazimine and dapsone for treating leprosy in children, provided free of charge through prepackaged blister packs. However, current formulations are not suited to younger children, with limited dosing flexibility, difficulties in administration and a lack of age-appropriate formulations, particularly for children under 10 years of age.

To address dosing challenges in younger children, harmonized weight-banded dosing is being developed for children aged 2 to under 10 years, informed by pharmacokinetic modelling and simulation. These recommendations enable the use of existing MDT blister packs, with appropriate adjustments, to achieve predicted adult-equivalent drug exposures while remaining within established paediatric safety margins.

Building on this work and recognizing the remaining formulation gaps, the WHO Paediatric Drug Optimization exercise for leprosy (PADO-leprosy) reviewed available medicines for treatment, prevention and management of leprosy reactions, prioritizing the development of rifampicin 100 mg scored dispersible tablets and dapsone 50 mg scored dispersible tablets. The exercise also identified opportunities to improve access to existing age-appropriate formulations, including clofazimine dispersible tablets by leveraging synergies with TB programmes, and highlighted the need for more suitable prednisolone formulations.

PADO-leprosy also reviewed emerging therapies and prioritized bedaquiline, telacebec, dovramilast and rifapentine for further paediatric investigation, recognizing their potential to shorten treatment, improve prevention and provide safer alternatives for managing leprosy reactions. The exercise emphasized the need to initiate paediatric studies early, including younger children, and identified research priorities to optimize dosing, improve medicine acceptability and facilitate regulatory approval and equitable access.

Portfolio products

8 products · PADO-leprosy, since 2026
● Access list: 2    ● Priority list: 2    ● Watch list: 4
2 Access
2 Priority
4 Watch

PADO-leprosy access list 2
Clofazimine
50 mg dispersible tablets
Prednisolone
age-appropriate formulations (soluble, dispersible tablet; orodispersible tablets)
PADO-leprosy priority list 2
Rifampicin
100 mg scored, dispersible tablets
Dapsone
50 mg scored, dispersible tablets
PADO-leprosy watch list 4
Bedaquiline
Telacebec
Dovramilast
Rifapentine

PADO report

Paediatric drug optimization for leprosy: meeting report, 28–29 April and 14 May 2026
This report presents the outcomes of the paediatric drug optimization (PADO) exercise for leprosy, convened by WHO in April and May 2026 to identify short-...

Contact

Vivek Lal
Email: vlal@who.int

Related publications

Guidelines for the diagnosis, treatment and prevention of leprosy

The Guidelines for the Diagnosis, Treatment and Prevention of Leprosy provide state-of-the-art knowledge and evidence on leprosy diagnosis, treatment and...

Operational Manual 2016 – Global Leprosy Strategy 2016−2020. Accelerating towards a leprosy-free world

The “Global Leprosy Strategy 2016–2020, Accelerating towards a leprosy-free world”, was officially launched on 20 April 2016. Its overall...

News